Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gelofusine versus HES 130/0.4 in CABG pump priming and coagulation
NL-OMON36390Phase 4Active, not recruiting
- Sponsor
- Amphia Ziekenhuis
- Start
- Jun 2011
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of gelatin and hetastarch in coronary arteriosclerosis, sponsored by Amphia Ziekenhuis. Primary endpoints: Thoracic drain output at 1 hour, Thoracic drain output at 3 hours and 3 more. Started Jun 2011; status: active, not recruiting.
02
Drugs
gelatinhetastarch
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON36390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36390.